Matthew E. Ros
COO & Interim Corporate SecretaryMr. Matthew E. Ros, also known as Matt, is Chief Operating Officer and Interim Corporate Secretary of Jasper Therapeutics, Inc. since July 16, 2026. He was Chief Operating Officer of Verastem, Inc. since January 2025 until December 2025. He served as an Executive Vice President at Epizyme, Inc. since September 2020 until October 31, 2021 and Chief Strategy and Business Officer since September 2018 until October 31, 2021 and also its Principal Financial Officer since July 16, 2021 until October 31, 2021 and served as its Chief Operating Officer from May 2016 to September 2018. Most recently, Mr. Ros served as Chief Executive Officer and Director of Fore Biotherapeutics Inc., a clinical-stage precision oncology company from April 2022 to August 2023. Mr. Ros served as principal financial officer of Epizyme, Inc. from January 31, 2019 to August 2019. Mr. Ros served as Senior Vice President of Commercial Operations at Ariad Pharmaceuticals Inc., since January 2009. He served as Vice President of Commercial Operations at Ariad Pharmaceuticals Inc., from August 2008 to January 2009. He served as Vice President of Oncology Marketing at Ariad Pharmaceuticals Inc., from November 2007 to August 2008. From October 2007 to June 2010, Mr. Ros worked at ARIAD Pharmaceuticals, Inc. He was responsible for planning and leading the U.S. launch of deforolimus with colleagues from Merck & Co., Inc. and preparing the market for ARIAD's growing pipeline of oncology products, including its new multi-targeted kinase inhibitor, AP24534. He joined Ariad in 2007. From September 2010 to May 2016, Mr. Ros served in increasing levels of responsibility at Sanofi, a multinational pharmaceutical company and served as its Chief Operating Officer/Global Head of the Oncology Business unit from December 2014 to May 2016. Mr. Ros served in the rare disease business of Genzyme, a Sanofi company, where he served as Vice President and Franchise Head of its Pompe disease unit from September 2012 to December 2014. Mr. Ros served as the Associate Vice President and Iniparib Global Brand Leader in Sanofi’s Oncology Business unit from September 2010 to September 2012. He has experience in sales, marketing, franchise strategy and operations leadership in both global pharmaceutical and early-stage biotechnology companies. He held a series of senior positions at Bristol-Myers Squibb Company (BMS). He served as Senior Director and U.S. Commercial Lead at Bristol-Myers Squibb. He played a key role in the launch and commercialization of BMS's oncology products, ixabepilone (Ixempra(TM)) and dasatinib (Sprycel®), as well as the early development of cetuximab (Erbitux®). He served on the Board of Trustees of CancerCARE. Mr. Ros serves as an Independent Director at Cogent Biosciences, Inc. (formerly known as Unum Therapeutics Inc.) since July 29, 2019. He started his pharmaceutical career in Bristol-Myers Squibb’s Oncology Division, serving in roles with increasing responsibility from 1990 to 2007. Mr. Ros received BS in Business Administration from the State University of New York, College at Plattsburgh and completed the Executive Education Program in Finance and Accounting for the Non-Financial Manager at Wharton School of the University of Pennsylvania.
Positions
- Company NameJasper Therapeutics, Inc.Stock CodeJSPRPositionCOO & Interim Corporate SecretaryColleagues
- JSJeetinder Singh MahalPresident, CEO, Interim CFO & Director
- TGThomas G. WiggansChairperson of the Board
- MFMatthew FordSenior Vice President of Human Resources
- LPLisa PittSenior Vice President of Regulatory Affairs
- WSWenru SongExecutive VP and Head of R&D
- KVKurt von EmsterDirector
- SLSvetlana LucasDirector
- PJPatrick James CrutcherDirector
